J&J Device Businesses Return To Growth Led By Electrophysiology And Surgery
The health care giant’s medical device revenues grew 8.8% in the first quarter, reflecting the recovery of interventions and surgeries since the start of the pandemic.
You may also be interested in...
J&J, Smith & Nephew, Stryker, Zimmer Biomet and other companies in the orthopedic and spine surgery space have welcomed a recent rebound in orthopedic device demand, but the volume of elective knee surgeries is still behind its pre-pandemic level.
Among the company's many milestones in the first quarter, the FDA approved its Therasphere radiation seed device, a major building block of the company's interventional oncology business.
Recovering pharmaceutical and medical device revenues at J&J hint at the green shoots germinating from the pandemic. Roche’s COVID-19 diagnostics revenue growth was its own green shoot, but can these be maintained as the pandemic evolves?